Tumor Biology

, Volume 36, Issue 4, pp 2257–2261 | Cite as

Prognostic role of serum carbohydrate antigen 19-9 levels in patients with resectable hepatocellular carcinoma

  • Jinyan Zhang
  • Tao Huang
  • Fan Zhang
  • Junming Xu
  • Guoqing Chen
  • Xiaoliang Wang
  • Li Huang
  • Zhihai Peng
Research Article

Abstract

Serum levels of carbohydrate antigen 19-9 (CA 19-9) were shown to be associated with poorer prognosis in several cancers, but the prognostic role of CA 19-9 levels in patients with hepatocellular carcinoma was unclear. A retrospective cohort of 97 patients with resectable hepatocellular carcinoma was performed to assess the prognostic role of CA 19-9 levels on overall survival in hepatocellular carcinoma. Both Kaplan-Meier product-limit method and multivariate analysis were performed to determine the prognostic role of CA 19-9 levels. The results indicated that among those 97 patients, 24 (24.7 %) had elevated preoperative CA 19-9 levels (≥37 U/mL). Elevated serum CA 19-9 levels did not correlate with patient age, gender, tumor size, tumor stage, diabetes, and hepatitis B virus (HBV) infection. Kaplan-Meier product-limit method showed that patients with elevated CA 19-9 levels had poorer survival than those with normal CA 19-9 levels (log-rank test P < 0.001). Multivariate analysis showed that elevated CA 19-9 level was a significantly independent predictor of poorer overall survival (hazard ratio [HR] = 2.56; 95 % confidence interval [95 % CI] 1.41–4.64, P = 0.002). In addition, tumor stages and multiple tumors were also independent predictors of poorer overall survival in hepatocellular carcinoma (P < 0.01). In conclusion, serum CA 19-9 levels have an independent prognostic role in patients with resectable hepatocellular carcinoma. Elevated CA 19-9 level is significantly associated with poorer overall survival in hepatocellular carcinoma.

Keywords

Hepatocellular carcinoma Carbohydrate antigen 19-9 Overall survival 

Notes

Acknowledgments

This work was supported by National Natural Science Foundation of China (81200328) and Shanghai Natural Science Foundation (12ZR1424100).

Conflicts of interest

None.

References

  1. 1.
    Li G, Zheng Z. Toll-like receptor 3 genetic variants and susceptibility to hepatocellular carcinoma and HBV-related hepatocellular carcinoma. Tumor Biol. 2013;34(3):1589–94.CrossRefGoogle Scholar
  2. 2.
    Breuhahn K, Gores G, Schirmacher P. Strategies for hepatocellular carcinoma therapy and diagnostics: lessons learned from high throughput and profiling approaches. Hepatology. 2011;53(6):2112–21.CrossRefPubMedGoogle Scholar
  3. 3.
    Tanaka M, Katayama F, Kato H, Tanaka H, Wang J, Qiao YL, et al. Hepatitis b and c virus infection and hepatocellular carcinoma in China: a review of epidemiology and control measures. J Epidemiol. 2011;21(6):401–16.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Aravalli RN, Steer CJ, Cressman EN. Molecular mechanisms of hepatocellular carcinoma. Hepatology. 2008;48(6):2047–63.CrossRefPubMedGoogle Scholar
  5. 5.
    Kaseb AO, Morris JS, Hassan MM, Siddiqui AM, Lin E, Xiao L, et al. Clinical and prognostic implications of plasma insulin-like growth factor-1 and vascular endothelial growth factor in patients with hepatocellular carcinoma. J Clin Oncol. 2011;29(29):3892–9.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Li W, Cai HX, Ge XM, Li K, Xu WD, Shi WH. Prognostic significance of BMP7 as an oncogene in hepatocellular carcinoma. Tumor Biol. 2013;34(2):669–74.CrossRefGoogle Scholar
  7. 7.
    Villanueva A, Minguez B, Forner A, Reig M, Llovet JM. Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med. 2010;61(1):317–28.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Galli C, Basso D, Plebani M. Ca 19-9: handle with care. Clin Chem Lab Med. 2013;51(7):1369–83.CrossRefPubMedGoogle Scholar
  9. 9.
    Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (ca 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33(3):266–70.CrossRefPubMedGoogle Scholar
  10. 10.
    John AR, Haghighi KS, Taniere P, Esmat ME, Tan YM, Bramhall SR. Is a raised CA 19-9 level diagnostic for a cholangiocarcinoma in patients with no history of sclerosing cholangitis? Dig Surg. 2006;23(5–6):319–24.PubMedGoogle Scholar
  11. 11.
    Zhang S, Chen Y, Zhu Z, Ding Y, Ren S, Zuo Y. Differential expression of carbohydrate antigen 19-9 in human colorectal cancer: a comparison with colon and rectal cancers. Mol Clin Oncol. 2013;1(6):1072–8.PubMedPubMedCentralGoogle Scholar
  12. 12.
    Mohri Y, Tanaka K, Ohi M, Saigusa S, Yasuda H, Toiyama Y, et al. Identification of prognostic factors and surgical indications for metastatic gastric cancer. BMC Cancer. 2014;14(6):409.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Tsuji M, Kashihara T, Terada N, Mori H. An immunohistochemical study of hepatic atypical adenomatous hyperplasia, hepatocellular carcinoma, and cholangiocarcinoma with alpha-fetoprotein, carcinoembryonic antigen, ca19-9, epithelial membrane antigen, and cytokeratins 18 and 19. Pathol Int. 1999;49(4):310–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Kim KH, Lee SG, Park EH, Hwang S, Ahn CS, Moon DB, et al. Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Ann Surg Oncol. 2009;16(3):623–9.CrossRefPubMedGoogle Scholar
  15. 15.
    Pissaia Jr A, Bernard D, Scatton O, Soubrane O, Conti F, Calmus Y. Significance of serum tumor markers carcinoembryonic antigen, ca 19-9, ca 125, and ca 15-3 in pre-orthotopic liver transplantation evaluation. Transplant Proc. 2009;41(2):682–4.CrossRefPubMedGoogle Scholar
  16. 16.
    Tao LY, Cai L, He XD, Liu W, Qu Q. Comparison of serum tumor markers for intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Am Surg. 2010;76(11):1210–3.PubMedGoogle Scholar
  17. 17.
    Ballehaninna UK, Chamberlain RS. Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9. Tumor Biol. 2013;34(6):3279–92.CrossRefGoogle Scholar
  18. 18.
    Bauer TM, El-Rayes BF, Li X, Hammad N, Philip PA, Shields AF, et al. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials. Cancer. 2013;119(2):285–92.CrossRefPubMedGoogle Scholar
  19. 19.
    Narita Y, Taniguchi H, Komori A, Nitta S, Yamaguchi K, Kondo C, et al. Ca19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy. Cancer Chemother Pharmacol. 2014;73(2):409–16.CrossRefPubMedGoogle Scholar
  20. 20.
    Liu SL, Song ZF, Hu QG, Shan D, Hu SB, Li J, et al. Serum carbohydrate antigen (ca) 19-9 as a prognostic factor in cholangiocarcinoma: a meta-analysis. Front Med China. 2010;4(4):457–62.CrossRefPubMedGoogle Scholar
  21. 21.
    Xiao J, He X, Wang Z, Hu J, Sun F, Qi F, et al. Serum carbohydrate antigen 19-9 and prognosis of patients with gastric cancer. Tumour Biol. 2014;35(2):1331–4.CrossRefPubMedGoogle Scholar
  22. 22.
    Uchino K, Tateishi R, Shiina S, Kanda M, Masuzaki R, Kondo Y, et al. Hepatocellular carcinoma with extrahepatic metastasis: clinical features and prognostic factors. Cancer. 2011;117(19):4475–83.CrossRefPubMedGoogle Scholar
  23. 23.
    Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology. 2011;140(5):1410–26.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Villanueva A, Hoshida Y, Battiston C, Tovar V, Sia D, Alsinet C, et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology. 2011;140(5):1501–12.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Zhou H, Huang H, Shi J, Zhao Y, Dong Q, Jia H, et al. Prognostic value of interleukin 2 and interleukin 15 in peritumoral hepatic tissues for patients with hepatitis b-related hepatocellular carcinoma after curative resection. Gut. 2010;59(12):1699–708.CrossRefPubMedGoogle Scholar
  26. 26.
    Zhao YM, Wang L, Dai Z, Wang DD, Hei ZY, Zhang N, et al. Validity of plasma macrophage migration inhibitory factor for diagnosis and prognosis of hepatocellular carcinoma. Int J Cancer. 2011;129(10):2463–72.CrossRefPubMedGoogle Scholar
  27. 27.
    Ding T, Xu J, Zhang Y, Guo RP, Wu WC, Zhang SD, et al. Endothelium-coated tumor clusters are associated with poor prognosis and micrometastasis of hepatocellular carcinoma after resection. Cancer. 2011;117(21):4878–89.CrossRefPubMedGoogle Scholar
  28. 28.
    Zhou L, Zhang N, Li QJ, Sun W, Zhang Y, Wang DS, et al. Association between high levels of notch 1 expression and high invasion and poor overall survival in hepatocellular carcinoma. Tumor Biol. 2013;34(1):543–53.CrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Jinyan Zhang
    • 1
  • Tao Huang
    • 2
  • Fan Zhang
    • 1
  • Junming Xu
    • 1
  • Guoqing Chen
    • 1
  • Xiaoliang Wang
    • 1
  • Li Huang
    • 1
  • Zhihai Peng
    • 1
  1. 1.Department of General Surgery, Shanghai First People’s HospitalShanghai Jiaotong UniversityShanghaiChina
  2. 2.Clinical LaboratoryBaoshan Branch of Shanghai First People’s HospitalShanghaiChina

Personalised recommendations